EU/3/19/2162: Orphan designation for the treatment of Stargardt's disease

Emixustat hydrochloride

Table of contents

Overview

On 29 May 2019, orphan designation (EU/3/19/2162) was granted by the European Commission to Pharma Gateway AB, Sweden, for emixustat hydrochloride for the treatment of Stargardt’s disease.

Key facts

Active substance
Emixustat hydrochloride
Intended use
Treatment of Stargardt's disease
Orphan designation status
Positive
EU designation number
EU/3/19/2162
Date of designation
29/05/2019
Sponsor

Pharma Gateway AB
Johanneslundsvägen 2
Hammarby
194 61 Upplands Väsby
Stockholms Lan
Sweden
Tel. +46 8 590 778 00
E-mail: info@pharmagateway.eu

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating